Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
June 10th, 2025
1.5K views
Here, we present a standardized protocol for detecting prostate cancer using stimulated Raman histology (SRH) on biopsy samples due to advantages over traditional histopathology, focusing on sample preparation, imaging, and artificial intelligence to improve the cancer-to-tissue ratio. Additionally, it supports biobanking for transcriptomics, organoid or xenograft models, and identification of intraoperative surgical margins.
Overview
This article presents a standardized protocol for detecting prostate cancer using stimulated Raman histology (SRH) on biopsy samples. The protocol emphasizes advantages over traditional histopathology, focusing on sample preparation, imaging, and the use of artificial intelligence to enhance the cancer-to-tissue ratio.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Histopathology
Background
- Prostate cancer detection is critical for effective treatment.
- Traditional histopathology has limitations in accuracy.
- Stimulated Raman histology offers a promising alternative.
- AI can improve diagnostic accuracy by enhancing imaging results.
Purpose of Study
- To establish a reliable protocol for prostate cancer detection.
- To improve the cancer-to-tissue ratio in biopsy samples.
- To facilitate biobanking for further research.
Methods Used
- Sample preparation techniques for SRH.
- Imaging protocols to capture high-quality results.
- Integration of artificial intelligence in analysis.
- Support for biobanking and model development.
Main Results
- Demonstrated effectiveness of SRH in detecting prostate cancer.
- Improved imaging results with AI assistance.
- Established protocols for sample preparation and analysis.
- Supported biobanking initiatives for future studies.
Conclusions
- SRH is a viable alternative to traditional histopathology.
- AI enhances the diagnostic capabilities of SRH.
- The protocol can aid in surgical margin identification.
Frequently Asked Questions
What is stimulated Raman histology?
Stimulated Raman histology (SRH) is an imaging technique that provides high-resolution images of tissue samples, allowing for better cancer detection.
How does AI improve cancer detection?
AI algorithms can analyze imaging data to enhance the accuracy of cancer detection by improving the cancer-to-tissue ratio.
What are the advantages of SRH over traditional histopathology?
SRH offers faster results, higher resolution images, and the ability to analyze samples without the need for staining.
Can this protocol support biobanking?
Yes, the protocol is designed to facilitate biobanking for further research and analysis.
What is the significance of identifying surgical margins?
Identifying surgical margins is crucial for ensuring that all cancerous tissue is removed during surgery, reducing the risk of recurrence.
Executive Industry Relevance
Rapid, label-free detection of prostate cancer in biopsy samples using stimulated Raman histology (SRH) with AI integration addresses a critical bottleneck in early discovery and diagnostic workflows. This approach enhances predictive confidence and accelerates decision-making at key inflection points in oncology R&D pipelines. The protocol's compatibility with biobanking and downstream molecular analyses supports translational continuity and portfolio prioritization.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables precise differentiation of cancerous versus benign tissue using molecular vibrational signatures.
- Supports functional target validation by correlating SRH imaging with molecular features relevant to disease mechanisms.
- Facilitates biological de-risking by providing quantitative, reproducible tissue characterization.
Screening & Assay Development
- Prepares validated, label-free tissue samples for high-throughput imaging and analysis workflows.
- Standardizes imaging outputs, supporting reproducibility and assay scalability across studies.
- Enables rapid, quantitative assessment of biopsy samples for downstream screening or compound evaluation.
Translational & Preclinical Research
- Aligns imaging outputs with biobanking and transcriptomic workflows for integrated biomarker discovery.
- Supports continuity from tissue acquisition through preclinical model development, including xenograft studies.
- Provides a platform for intraoperative margin assessment, informing translational research on surgical outcomes.
Pipeline & Workflow Integration
SRH with AI analysis integrates at the interface of tissue acquisition, early discovery, and translational research, bridging diagnostic imaging with molecular and preclinical workflows.
- Discovery Biology: Enables hypothesis testing and pathway clarification through molecularly resolved tissue imaging.
- Screening: Delivers standardized, quantitative imaging outputs suitable for assay development and compound triage.
- Analytics: Provides high-accuracy, AI-driven classification of tissue states to support comparative analyses.
- Translational Research: Facilitates alignment of imaging data with biobanking and downstream omics studies.
- Enterprise Reuse: Establishes a reusable imaging and analysis platform for diverse oncology and tissue-based R&D programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in tissue-based target validation.
- Operational Value: Accelerates diagnostic workflows and standardizes imaging outputs for scalable R&D operations.
- Strategic Value: Improves go/no-go decisions and capital efficiency by enabling near-real-time tissue assessment.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of oncology assets based on robust tissue characterization.
Implementation Considerations
- Requires expertise in SRH imaging, AI model integration, and tissue handling protocols.
- Demands access to SRS microscopy instrumentation and computational infrastructure for AI analysis.
- Necessitates cross-team standardization of imaging and data analysis workflows.
- Adaptation may be needed for different tissue types or disease models beyond prostate cancer.
- Further validation is required for widespread adoption and integration into clinical or translational pipelines.
Biopharma FAQs
Why does null hypothesis testing matter for SRH-based target validation?
Null hypothesis testing ensures that observed differences in SRH imaging between cancerous and benign tissues are statistically significant, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation fit SRH-AI discovery workflows?
Isolating variables such as specific vibrational frequencies (CH2 and CH3 bonds) allows the SRH-AI workflow to attribute tissue classification outcomes directly to molecular features, enhancing mechanistic clarity in discovery pipelines.
What do quantitative dependent variable measurements enable in SRH imaging?
Quantitative measurements of vibrational signal intensities enable objective comparison of tissue states, supporting reproducible classification and facilitating downstream analytics and decision-making in R&D.
Why are replication requirements critical for cross-functional SRH-AI collaboration?
Replication ensures that SRH-AI imaging and classification results are consistent across samples and operators, enabling reliable data sharing and integration between discovery, translational, and preclinical teams.
What statistical analysis capabilities are required before SRH-AI implementation?
Robust statistical analysis is needed to validate AI model accuracy, assess classification thresholds, and confirm reproducibility, ensuring that SRH-AI outputs meet enterprise R&D standards for implementation.
